Adicet Bio (ACET)

• Market cap: $60.8M
• 1 day: -2.65%
• 5 days: -17.42%
• 1 month: -13.28%
• 3 months: -24.52%
• 6 months: -48.24%
• Year to date: -24.52%
• 1 year: -69.38%
• 5 years: -27.23%
• 10 years: -95.65%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Employees: 152

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

2% more funds holding

Funds holding: 63 [Q3] → 64 (+1) [Q4]

1.02% more ownership

Funds ownership: 68.9% [Q3] → 69.92% (+1.02%) [Q4]

32% less capital invested

Capital invested by funds: $81.8M [Q3] → $55.4M (-$26.3M) [Q4]

38% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 24

48% less call options, than puts

Call options by funds: $27K | Put options by funds: $52K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 852% upside
• Avg. target: $7 852% upside
• High target: $7 852% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Guggenheim Yatin Suneja 27% 1-year accuracy 9 / 33 met price target

852% upside $7

Buy Reiterated

21 Mar 2025